Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1964
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1968 2
1971 1
1972 5
1973 2
1974 4
1978 4
1980 4
1981 2
1982 4
1983 2
1984 6
1985 3
1986 4
1987 8
1988 8
1989 5
1990 8
1991 10
1992 13
1993 24
1994 14
1995 18
1996 20
1997 15
1998 8
1999 21
2000 26
2001 31
2002 20
2003 19
2004 19
2005 18
2006 25
2007 22
2008 17
2009 39
2010 27
2011 27
2012 23
2013 32
2014 38
2015 38
2016 36
2017 35
2018 29
2019 27
2020 35
2021 43
2022 34
2023 58
2024 41
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

873 results

Results by year

Filters applied: . Clear all
Page 1
Hypertrophic cardiomyopathy: the future of treatment.
Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Tuohy CV, et al. Eur J Heart Fail. 2020 Feb;22(2):228-240. doi: 10.1002/ejhf.1715. Epub 2020 Jan 9. Eur J Heart Fail. 2020. PMID: 31919938 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility, and reduced compliance. It is the most common inherited monogenic cardiac conditi
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in l
Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review.
Bishev D, Fabara S, Loseke I, Alok A, Al-Ani H, Bazikian Y. Bishev D, et al. Heart Lung Circ. 2023 Sep;32(9):1049-1056. doi: 10.1016/j.hlc.2023.05.019. Epub 2023 Jul 14. Heart Lung Circ. 2023. PMID: 37453852 Free article. Review.
BACKGROUND: Current pharmacological options for hypertrophic cardiomyopathy (HCM) are not disease-specific; while it treats symptoms, mavacamten targets the underlying pathology. ...The three endpoints used in the evaluation of studies were reduction in NYHA class, …
BACKGROUND: Current pharmacological options for hypertrophic cardiomyopathy (HCM) are not disease-specific; while it treats sy …
Cardiomyopathies: An Overview.
Ciarambino T, Menna G, Sansone G, Giordano M. Ciarambino T, et al. Int J Mol Sci. 2021 Jul 19;22(14):7722. doi: 10.3390/ijms22147722. Int J Mol Sci. 2021. PMID: 34299342 Free PMC article. Review.
The search keywords were "cardiomyopathies, sudden cardiac arrest, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy, arrhythmogenic cardiomyopathy (ARCV), takotsubo syndrome". RESULTS: Hypertrophic
The search keywords were "cardiomyopathies, sudden cardiac arrest, dilated cardiomyopathy (DCM), hypertrophic cardiomyopath
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Braunwald E, et al. Eur Heart J. 2023 Nov 21;44(44):4622-4633. doi: 10.1093/eurheartj/ehad637. Eur Heart J. 2023. PMID: 37804245 Free PMC article. Review.
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mav …
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatmen …
Applications of Gene Therapy in Cardiomyopathies.
Argiro A, Bui Q, Hong KN, Ammirati E, Olivotto I, Adler E. Argiro A, et al. JACC Heart Fail. 2024 Feb;12(2):248-260. doi: 10.1016/j.jchf.2023.09.015. Epub 2023 Oct 7. JACC Heart Fail. 2024. PMID: 37966402 Review.
Furthermore, promising results have been shown in animal models of gene therapy in hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy. This review summarizes the gene therapy techniques, the toxicity risk associated with adeno-associated virus deli …
Furthermore, promising results have been shown in animal models of gene therapy in hypertrophic cardiomyopathy and arrhythmoge …
A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
Yacoub MS, El-Nakhal T, Hasabo EA, Shehata N, Wilson K, Ismail KH, Bakr MS, Mohsen M, Mohamed A, Abdelazim E, Ali HT, Soliman Z, Sayed A, Abdelsayed K, Caliskan K, Soliman O. Yacoub MS, et al. Heart Fail Rev. 2024 Mar;29(2):479-496. doi: 10.1007/s10741-023-10375-6. Epub 2023 Dec 19. Heart Fail Rev. 2024. PMID: 38112937 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable myocardial disorder worldwide. ...Mavacamten showed a statistically significant increase in the frequency of the primary composite endpoint (RR = 1.92, 95% CI [1.28, 2.88]), 1 NYHA class improveme
Hypertrophic cardiomyopathy (HCM) is the most common heritable myocardial disorder worldwide. ...Mavacamten showed a statistic
Hypertrophic cardiomyopathy: a systematic review.
Maron BJ. Maron BJ. JAMA. 2002 Mar 13;287(10):1308-20. doi: 10.1001/jama.287.10.1308. JAMA. 2002. PMID: 11886323 Review.
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic cardiac disease caused by a variety of mutations in genes encoding sarcomeric proteins and characterized by a …
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardio
Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Sebastian SA, Padda I, Lehr EJ, Johal G. Sebastian SA, et al. Am J Cardiovasc Drugs. 2023 Sep;23(5):519-532. doi: 10.1007/s40256-023-00599-0. Epub 2023 Aug 1. Am J Cardiovasc Drugs. 2023. PMID: 37526885 Review.
Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower left ventricular outflow tract (LVOT) gradients and improve heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). Based on the REDWOOD-HC …
Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower left ventricular outflow tract (LVOT) gradie …
Apical Hypertrophic Cardiomyopathy: The Variant Less Known.
Hughes RK, Knott KD, Malcolmson J, Augusto JB, Mohiddin SA, Kellman P, Moon JC, Captur G. Hughes RK, et al. J Am Heart Assoc. 2020 Mar 3;9(5):e015294. doi: 10.1161/JAHA.119.015294. Epub 2020 Feb 28. J Am Heart Assoc. 2020. PMID: 32106746 Free PMC article. Review. No abstract available.
Hypertrophic Cardiomyopathy 2020.
Kogut J, Popjes ED. Kogut J, et al. Curr Cardiol Rep. 2020 Oct 6;22(11):154. doi: 10.1007/s11886-020-01381-3. Curr Cardiol Rep. 2020. PMID: 33025145 Review.
PURPOSE OF REVIEW: To briefly review the pathophysiology and natural history of hypertrophic cardiomyopathy (HCM) and to describe the diagnosis, assessment, and contemporary management strategies. ...Several medical therapies have been shown to reduce symptoms and i …
PURPOSE OF REVIEW: To briefly review the pathophysiology and natural history of hypertrophic cardiomyopathy (HCM) and to descr …
873 results